Ipsen SA Reports Strong Financial Growth in H1 2025 with Increased Net Profit and Revenue
Ipsen SA has reported strong financial results for the first half of 2025, with a 9.8% increase in sales and a raised annual sales outlook.
One minute to read
Ipsen Pharmaceuticals Reports Key Financial Metrics in 2025 Half-Year Statement
Ipsen Pharmaceuticals has released its half-year statement for 2025, providing key financial metrics and valuation insights.
One minute to read
Ipsen SA’s Stock Soars as Strategic Buybacks and Growth Fuel Market Confidence
Ipsen SA, a French pharmaceutical company, has seen its stock price surge to levels above its 52-week high, driven by strategic share buybacks and a stable financial situation.
2 minutes to read
Ipsen SA Appoints New Executive VP to Drive Strategic Growth and Innovation
Ipsen SA has strengthened its leadership team and pipeline with the appointment of a new Executive Vice President and promising data on its drug IQIRVO, positioning the company for sustained growth and success.
2 minutes to read
Ipsen SA Reports 11.6% Q1 2025 Sales Growth, Driven by Strong Performance and Key Products
Ipsen SA reported a 11.6% sales growth in Q1 2025, driven by strong performance across all therapeutic areas and contributions from products Iqirvo and Bylvay.
One minute to read